Healthcare provider profile · identity verified

Theodore Mark Rutledge, MD

Internal Medicine · ADA, OK · NPI 1508942285

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	612	73
Losartan Potassium	Losartan Potassium	498	52
Amlodipine Besylate	Amlodipine Besylate	465	55
Fluticasone Propionate	Fluticasone Propionate	440	65
Gabapentin	Gabapentin	382	46
Synthroid	Levothyroxine Sodium	378	38
Atorvastatin Calcium	Atorvastatin Calcium	340	41
Omeprazole	Omeprazole	337	40
Montelukast Sodium	Montelukast Sodium	319	35
Pantoprazole Sodium	Pantoprazole Sodium	302	38
Hydrochlorothiazide	Hydrochlorothiazide	288	29
Albuterol Sulfate Hfa	Albuterol Sulfate	273	45
Enalapril Maleate	Enalapril Maleate	255	26
Famotidine	Famotidine	192	26
Metoprolol Succinate	Metoprolol Succinate	171	23
Ozempic	Semaglutide	161	20
Tamsulosin Hcl	Tamsulosin Hcl	156	22
Duloxetine Hcl	Duloxetine Hcl	151	18
Lisinopril	Lisinopril	150	23
Simvastatin	Simvastatin	147	14
Eliquis	Apixaban	140	22
Metformin Hcl	Metformin Hcl	127	16
Jardiance	Empagliflozin	126	18
Potassium Chloride	Potassium Chloride	123	19
Clopidogrel	Clopidogrel Bisulfate	118	15
Atenolol	Atenolol	111	12
Furosemide	Furosemide	108	18
Metoprolol Tartrate	Metoprolol Tartrate	104	12
Dulera	Mometasone/Formoterol	97	12
Diclofenac Sodium	Diclofenac Sodium	86	15
Carvedilol	Carvedilol	85	12
Ezetimibe	Ezetimibe	80	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	77	suppressed
Spiriva Respimat	Tiotropium Bromide	76	13
Trazodone Hcl	Trazodone Hcl	68	suppressed
Alendronate Sodium	Alendronate Sodium	67	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	64	suppressed
Sertraline Hcl	Sertraline Hcl	61	suppressed
Celecoxib	Celecoxib	58	suppressed
Metformin Hcl Er	Metformin Hcl	56	suppressed
Allopurinol	Allopurinol	54	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	52	suppressed
Klor-Con 10	Potassium Chloride	47	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	45	suppressed
Nitroglycerin	Nitroglycerin	43	suppressed
Meloxicam	Meloxicam	42	suppressed
Baclofen	Baclofen	37	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	37	suppressed
Spironolactone	Spironolactone	36	suppressed
Lactulose	Lactulose	34	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	33	suppressed
Labetalol Hcl	Labetalol Hcl	33	suppressed
Ondansetron Odt	Ondansetron	33	suppressed
Xarelto	Rivaroxaban	33	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	30	suppressed
Amiodarone Hcl	Amiodarone Hcl	29	suppressed
Levetiracetam	Levetiracetam	29	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	28	suppressed
Digoxin	Digoxin	28	suppressed
Alogliptin	Alogliptin Benzoate	27	suppressed
Citalopram Hbr	Citalopram Hydrobromide	27	suppressed
Acyclovir	Acyclovir	26	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	25	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Liothyronine Sodium	Liothyronine Sodium	24	suppressed
Glipizide Er	Glipizide	23	suppressed
Bupropion Hcl Sr	Bupropion Hcl	22	suppressed
Fenofibric Acid	Fenofibric Acid (Choline)	22	suppressed
Finasteride	Finasteride	22	suppressed
Pravastatin Sodium	Pravastatin Sodium	22	suppressed
Tresiba Flextouch U-200	Insulin Degludec	20	suppressed
Irbesartan	Irbesartan	19	suppressed
Prazosin Hcl	Prazosin Hcl	19	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Topiramate	Topiramate	18	suppressed
Entresto	Sacubitril/Valsartan	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Sotalol Af	Sotalol Hcl	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Prasugrel Hcl	Prasugrel Hcl	15	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Prednisone	Prednisone	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Ranolazine Er	Ranolazine	14	suppressed
Torsemide	Torsemide	14	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Methenamine Hippurate	Methenamine Hippurate	12	suppressed
Methotrexate	Methotrexate Sodium	12	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	11	suppressed
Humira Pen	Adalimumab	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Olanzapine Odt	Olanzapine	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error